Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I mass balance and pharmacokinetics study of 14C-QLT091001 in healthy male subjects
NL-OMON35776Phase 1Active, not recruiting
- Sponsor
- QLT Inc.
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zuretinol in Fundus dystrophy, sponsored by QLT Inc. Primary endpoint: Biotransformation pathways, excretion routes and rates, and total recovery. Started Apr 2011; status: active, not recruiting.
02
Drugs
zuretinol
03
Conditions
Fundus dystrophy
Beyond the preview
Go deeper on NL-OMON35776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35776.